Special Issue "Frontiers of Radioimmunotherapy"
Deadline for manuscript submissions: closed (12 December 2014)
Dr. Rune Nilsson (Website)
Department of Oncology, Clinical Sciences, Lund University, Sweden
Interests: radioimmunotherapy; tumor immunology, immunotherapy; tumor microenvironment; antibody conjugates
Dr. Sophie E. Eriksson (Website)
Lund University Cancer Center (LUCC),Division of Oncology and Pathology, Department of Clinical Sciences, Lund University,Sweden
Interests: radioimmunotherapy; radionuclides; metastases; radiobiology; preclinical models
Radioimmunotherapy, which utilizes radiolabeled antibodies for targeting tumors, is now an established therapy for Non-Hodgkin lymphoma (NHL) patients. Clinical research is still on-going to further improve the therapy for these patients (e.g., by attempting to prolong the duration of the clinical response).
The majority of the current pre-clinical radioimmunotherapy research aims at transferring the clinical success of treating lymphoma to treating solid tumors. Solid tumors are generally more radioresistant than NHL and require higher absorbed doses for therapeutic effect. Poor tumor accretion and the unfavorable pharmacokinetics of radiolabeled antibodies are major impediments that limit the efficacy of radioimmunotherapy in solid tumors. Ways of increasing the therapeutic outcome may involve pretargeting (where an unlabeled antibody construct is followed by a radiolabeled low molecular weight component that binds to the antibody construct), fractionated radioimmunotherapy, and the use of alpha-particle emitting radionuclides that have a higher radiobiological effect than that of the generally used beta-particle emitters. Radioimmunotherapy with alpha-particle emitters has been proposed for treating disseminated or residual diseases (due the short range of the particles).
Clinically, the consensus is that radioimmunotherapy is best used to treat small tumors (instead of bulky diseases). An interesting area for clinical research is the evaluation of combining radioimmunotherapy with other modalities (e.g. chemotherapy, tyrosine kinase inhibitors or immunotherapy).
The articles in this Special Issue of IJMS will cover a broad range of topics, from both pre-clinical and clinical research, which concern the improvement of radioimmunotherapy, so as to give the reader an update on the latest developments.
Dr. Rune Nilsson
Dr. Sophie E. Eriksson
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed Open Access monthly journal published by MDPI.
- radionuclide therapy
- alpha emitter
- beta emitter
- tumor therapy